Niki BioSolutions' subsidiary, DiamiR Biosciences, will provide Apolipoprotein E (APOE) genotyping services to Progressive Medical Research (PMR) for their clinical and translational research programs. This collaboration enhances PMR's research capabilities in areas like Alzheimer's disease and cardiovascular health by integrating high-quality genetic data.
Niki BioSolutions' wholly-owned subsidiary, DiamiR Biosciences, has secured an agreement to provide Apolipoprotein E (APOE) genotyping services to Progressive Medical Research (PMR). This is a positive development for Niki BioSolutions as it expands the reach and utilization of its CAP and CLEP approved testing platform, generating revenue and validating its expertise in genetic testing. For PMR, it means access to critical genetic data for their ongoing clinical and translational research, particularly in Alzheimer's disease, which could accelerate their research outcomes. The short-term implication is a minor revenue boost for Niki BioSolutions and enhanced research efficiency for PMR. Long-term, this collaboration could lead to further partnerships and solidify DiamiR's position as a key provider of genetic testing services in the research community, offering an opportunity for Niki BioSolutions to grow its diagnostics segment.